论文部分内容阅读
目的 探讨培菲康在治疗小儿单纯性肾病综合征 (SNS)中的作用。方法 5 1例SNS患儿随机分为培菲康治疗组 (Ⅰ组 ,n =3 5 )和强的松对照组 (Ⅱ组 ,n =16)。两组均采用强的松中程疗法 ,Ⅰ组另加培菲康 ,疗程 3个月。监测患儿 8周内缓解率及 3个月内的感染率、反复或复发率 ;治疗前和治疗后 3个月患儿血清可溶性白细胞介素 2受体 (sIL 2R)及血浆IgG、IgA、IgM水平 ,并与健康儿童比较。 结果 8周内缓解率Ⅰ组和Ⅱ组比较无显著性差异 (P >0 .0 5 ) ;治疗 3个月后 ,感染率Ⅰ组明显低于Ⅱ组 (P <0 .0 5 ) ;感染后反复或复发率 ,Ⅰ组明显低于Ⅱ组 (P <0 .0 5 ) ;血清slL 2R水平 ,Ⅰ组和Ⅱ组与治疗前比均显著下降 (P均 <0 .0 1) ,Ⅰ组下降显著大于Ⅱ组 (P <0 .0 5 ) ,并与正常组比较已无显著性差异性 (P >0 .0 5 ) ,Ⅱ组仍显著高于正常组 (P <0 .0 5 ) ;血浆IgG水平 ,Ⅰ组较治疗前和Ⅱ组上升明显 ,均有显著性差异 (P均 <0 .0 5 ) ,与正常组比较已无显著性差异 (P >0 .0 5 ) ,Ⅱ组仍显著低于正常组 (P <0 .0 5 ) ;血浆IgA、IgM三组间治疗前后均无显著性差异。 结论 培菲康对小儿SNS有一定的治疗和免疫调节作用。
Objective To investigate the role of Pefikon in the treatment of children with simple nephrotic syndrome (SNS). Method 5 One case of SNS were randomly divided into Pefikan treatment group (group Ⅰ, n = 35) and prednisone control group (group Ⅱ, n = 16). Two groups were used prednisone midrange therapy, group I plus Peifeikang, treatment for 3 months. The response rate, recurrence rate or recurrence rate within 8 weeks and the incidence of recurrence or recurrence within 8 weeks were measured. The levels of soluble interleukin 2 receptor (sIL 2R) and plasma IgG, IgA, IgM levels, and compared with healthy children. Results The remission rate within 8 weeks had no significant difference between group Ⅰ and group Ⅱ (P0.05). After 3 months of treatment, the infection rate in group Ⅰ was significantly lower than that in group Ⅱ (P0.05) (P <0.05). Serum slL 2R levels in group Ⅰ and group Ⅱ were significantly lower than those before treatment (all P <0.01), while in group Ⅰ (P <0.05), and there was no significant difference compared with normal group (P> 0.05), but the level in group Ⅱ was still significantly higher than that in normal group (P <0.05) ); The level of plasma IgG in groupⅠwas significantly higher than that before treatment and in groupⅡ (all P <0.05), there was no significant difference between the two groups (P> 0.05) Ⅱ group was still significantly lower than the normal group (P <0. 05); plasma IgA, IgM between the three groups before and after treatment no significant difference. Conclusion Pefikon has certain therapeutic and immunomodulatory effects on pediatric SNS.